GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » IntelliPharmaCeutics International Inc (OTCPK:IPCIF) » Definitions » Degree of Financial Leverage

IntelliPharmaCeutics International (IntelliPharmaCeutics International) Degree of Financial Leverage : 1.49 (As of Aug. 2023)


View and export this data going back to 1996. Start your Free Trial

What is IntelliPharmaCeutics International Degree of Financial Leverage?

Degree of Financial Leverage (DFL) measures the percentage change in EPS for a unit change in Earnings Before Interest and Taxes (EBIT). IntelliPharmaCeutics International's Degree of Financial Leverage for the quarter that ended in Aug. 2023 was 1.49. The higher Degree of Financial Leverage, the more volatile earnings will be.

The industry rank for IntelliPharmaCeutics International's Degree of Financial Leverage or its related term are showing as below:

IPCIF's Degree of Financial Leverage is ranked worse than
79.05% of 1499 companies
in the Biotechnology industry
Industry Median: 0.97 vs IPCIF: 1.49

IntelliPharmaCeutics International Degree of Financial Leverage Historical Data

The historical data trend for IntelliPharmaCeutics International's Degree of Financial Leverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

IntelliPharmaCeutics International Degree of Financial Leverage Chart

IntelliPharmaCeutics International Annual Data
Trend Nov13 Nov14 Nov15 Nov16 Nov17 Nov18 Nov19 Nov20 Nov21 Nov22
Degree of Financial Leverage
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.37 2.06 0.91 0.24 1.12

IntelliPharmaCeutics International Quarterly Data
Nov18 Feb19 May19 Aug19 Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23
Degree of Financial Leverage Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.84 1.12 1.09 1.06 1.49

Competitive Comparison of IntelliPharmaCeutics International's Degree of Financial Leverage

For the Biotechnology subindustry, IntelliPharmaCeutics International's Degree of Financial Leverage, along with its competitors' market caps and Degree of Financial Leverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


IntelliPharmaCeutics International's Degree of Financial Leverage Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, IntelliPharmaCeutics International's Degree of Financial Leverage distribution charts can be found below:

* The bar in red indicates where IntelliPharmaCeutics International's Degree of Financial Leverage falls into.



IntelliPharmaCeutics International Degree of Financial Leverage Calculation

IntelliPharmaCeutics International's Degree of Financial Leverage for the quarter that ended in Aug. 2023 is calculated as:

Degree of Financial Leverage=% Change in Earnings per Share (Diluted)**/% Change in EBIT
=( -0.092 (Aug. 2023) / -0.13 (Aug. 2022) - 1 )/( -2.885 (Aug. 2023) / -3.678 (Aug. 2022) - 1 )
=-0.2923/-0.2156
=1.36***

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** TTM data of EPS and EBIT was used to calculate Degree of Financial Leverage.
*** Please be aware that the Degree of Financial Leverage calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.


IntelliPharmaCeutics International  (OTCPK:IPCIF) Degree of Financial Leverage Explanation

Degree of Financial Leverage (DFL) is a leverage ratio that measures the sensitivity of a company’s Earnings per Share (EPS) to fluctuations in its operating income, also referred to as Earnings Before Interest and Taxes (EBIT), resulting from adjustments in its capital structure. DFL is an essential tool for companies to assess the appropriate level of debt or financial leverage in their capital structure. When EBIT remains relatively stable, it results in stable earnings and earnings per share. In such cases, the company may consider taking on substantial debt. However, for companies operating in industries with significant fluctuations in EBIT, it is advisable to keep debt at a manageable level.

The higher Degree of Financial Leverage, the more volatile earnings will be. Because interest is a fixed expense, leverage can amplify earnings and EPS. This is beneficial when EBIT is growing, but it can become problematic in tough economic conditions when EBIT is under pressure.

Be Aware

The use of financial leverage varies across different industries and business sectors, and the application of Degree of Financial Leverage (DFL) should be adjusted accordingly.


IntelliPharmaCeutics International Degree of Financial Leverage Related Terms

Thank you for viewing the detailed overview of IntelliPharmaCeutics International's Degree of Financial Leverage provided by GuruFocus.com. Please click on the following links to see related term pages.


IntelliPharmaCeutics International (IntelliPharmaCeutics International) Business Description

Traded in Other Exchanges
Address
30 Worcester Road, Toronto, ON, CAN, M9W 5X2
IntelliPharmaCeutics International Inc is a pharmaceutical company. The company is engaged in the research, development, and manufacturing of novel and generic controlled-release and targeted-release oral solid dosage drugs. Its patented Hypermatrix technology is a multidimensional controlled-release drug delivery platform that can be applied to the development of a range of existing and new pharmaceuticals. Its ongoing drug development programs are at various stages of development in therapeutic areas that include neurology, cardiovascular, GIT, and pain. The company's product, a generic of Focalin XR, is partnered with Par Pharmaceutical, Inc. and received FDA approval. It derives revenue from the United States.

IntelliPharmaCeutics International (IntelliPharmaCeutics International) Headlines

From GuruFocus

Intellipharmaceutics Reports Director Election Results

By ACCESSWIRE ACCESSWIRE 05-28-2022

Intellipharmaceutics Announces Fiscal Year 2020 Results

By ACCESSWIRE ACCESSWIRE 03-01-2021